继发性心脏淋巴瘤诊治研究进展  

Advances in the diagnosis and treatment of secondary cardiac lymphoma

作　　者：杨园园 史明霞[1] YANG Yuanyuan;SHI Mingxia(The First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)

机构地区：[1]昆明医科大学第一附属医院,昆明650032

出　　处：《实用医学杂志》2023年第9期1067-1071,共5页The Journal of Practical Medicine

基　　金：国家自然科学基金资助项目(编号:81760035)。

摘　　要：心脏淋巴瘤是一种少见的结外淋巴瘤,预后极差。继发性心脏淋巴瘤(secondary cardiac lymphoma,SCL)较原发性心脏淋巴瘤常见,多见于播散性淋巴瘤及高危组患者。由于继发性心脏淋巴瘤患者症状非特异性,本病常出现诊治延误且病死率高。部分患者甚至死后尸检才发现淋巴瘤累及心脏。目前继发性心脏淋巴瘤尚无系统诊疗指南,而早诊治对于提高该类患者的生存率极为重要。本文就继发性心脏淋巴瘤诊治最新研究进展作综述。Cardiac lymphoma is a rare form of extranodal lymphoma with an extremely poor prognosis.Sec⁃ondary cardiac lymphoma(SCL)is more common than primary cardiac lymphoma and is usually found in patients with disseminated lymphoma or advanced lymphoma.Patients with SCL often experience non⁃specific symptoms,which lead to a delay in diagnosis and treatment,and in some cases,SCL cannot be detected until a postmortem.There are no systematic guidelines for the diagnosis and treatment of SCL.The value of early diagnosis and therapy in enhancing survival rates cannot be underestimated.This article outlines the most recent developments in the diag⁃nosis and treatment of SCL.

关 键 词：心脏淋巴瘤 继发性 诊断 治疗 研究进展 

分 类 号：R551.2[医药卫生—血液循环系统疾病]